Immuneel Therapeutics is at the forefront of advancing cancer treatment in India through innovative cell and gene therapies, particularly focusing on Chimeric Antigen Receptor T cell (CAR-T) therapy. This approach utilizes genetically modified immune cells to specifically target and eliminate cancer cells, offering a promising alternative to traditional cancer treatments. Immuneel aims to make these advanced therapies affordable and accessible to the Indian population, addressing the significant gap in access to cutting-edge cancer treatments that currently exists in the country. Their flagship product, Qartemi®, is an autologous CD19 CAR-T cell therapy approved for treating relapsed and refractory Non-Hodgkin’s Lymphoma, showcasing their commitment to bringing transformative therapies to the market.

The company is also dedicated to expanding its research and development efforts to include a broader range of cancers and diseases. Immuneel's strategy involves not only enhancing existing CAR-T therapies but also exploring next-generation cellular immunotherapy platforms that could potentially treat solid tumors and other rare diseases. By collaborating with global partners, Immuneel seeks to innovate in the construction and design of therapies, aiming to develop allogeneic treatments that could provide off-the-shelf solutions for patients. This comprehensive approach positions Immuneel as a leader in the evolving landscape of cancer care in India, with a focus on improving patient outcomes and quality of life through personalized and effective treatment options.

India

A pioneering clinical stage startup company leading the Cell & Gene therapy revolution and are committed to bringing breakthrough cancer treatment to patients in India, making it accessible & affordable.

Immuneel Therapeutics

Company Details